-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $15 Price Target

Benzinga·03/30/2026 17:33:23
Listen to the news
HC Wainwright & Co. analyst Robert Burns reiterates Immix Biopharma (NASDAQ:IMMX) with a Buy and maintains $15 price target.